Filing Flows › Neogenomics (NEO) › Q3 2026
Neogenomics (NEO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 28, 2026
Neogenomics (NEO) reported revenue of $209M for the third quarter 2026 (Q3 2026), +11% from a year earlier and +4% from the quarter before. Operating margin was -3.8%, net loss $7.5M (3.6% of revenue).
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $209M | +4% | +11% |
| Operating profit | −$7.9M | — | — |
| Net earnings | −$7.5M | -437% | — |
| Operating cash flow | −$8.9M | -145% | -200% |
What changed
Revenue was $209.3M in Q3 2026, up 11% year over year and up 4% from the previous quarter. Client direct billing was the largest line at 65% of revenue. Commercial insurance added $12.2M year over year (up 38%), 57% of the total change.
Gross margin was 46.2%, up 3.3 points from Q3 2025. Operating costs exceeded revenue by $7.9M, an operating margin of -3.8%. Operating expenses fell 3% while revenue rose 11%. The fastest-growing cost line was Sales & marketing (+27%). The quarter ended with a net loss of $7.5M, after a profit of $2.2M the previous quarter.
Operating cash flow was −$8.9M. Non-cash charges added back $16.2M of depreciation and amortization and $8.8M of share-based compensation. Working capital and other items used $26.4M. Capital expenditures of $11.8M exceeded it, leaving free cash flow of −$20.7M.
Questions
What was Neogenomics' revenue in the third quarter 2026?
Neogenomics (NEO) reported revenue of $209M for the third quarter 2026 (Q3 2026), +11% from a year earlier and +4% from the quarter before.
Was Neogenomics profitable in the third quarter 2026?
Operating loss was $7.9M (-3.8% of revenue) and net loss $7.5M.
Source: Neogenomics 10-Q on SEC EDGAR.